 |
市場調查報告書
商品編碼
1705866
脊髓性肌肉萎縮症市場：按類型、治療方法、年齡層、給藥途徑、通路和地區分類Spinal Muscular Atrophy Market, by Type, by Treatment, by Age Group, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2025 - 2032 |
||||||
價格
簡介目錄
2025 年全球脊髓性肌肉萎縮症市場規模估計為 20.189 億美元，預計到 2032 年將達到 48.989 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 13.5%。
| 報告範圍 | 報告詳細資訊 | ||
|---|---|---|---|
| 基準年 | 2024 | 2025年的市場規模 | 20.189億美元 |
| 效能數據 | 從2020年到2024年 | 預測期 | 2025年至2032年 |
| 預測期：2025-2032年複合年成長率： | 13.50% | 2032年價值預測 | 48.989億美元 |
數字。 2025年脊髓性肌肉萎縮症各地區市場佔有率（%）
脊髓性肌肉萎縮症 (SMA) 是一種影響周邊神經系統、中樞神經系統和隨意肌肉運動（骨骼肌）的遺傳性疾病。 SMA 是肌肉性的，因為它主要影響那些不會接收神經細胞衝動的肌肉。萎縮是肌肉收縮的醫學術語，當肌肉不再接受神經細胞的刺激時就會發生這種情況。 SMA 是運動神經元疾病，導致脊髓中稱為運動神經元的神經細胞流失。它主要發生在嬰兒和兒童中，但也可能發生在成人中。 SMA 患者遺傳了兩個異常（突變）或缺失的運動神經元存活 1 (SMN1) 基因副本。
市場動態
預計預測期內市場主要參與者推出的新產品將推動市場成長。例如，2021年8月，在日本營運的藥廠中外製藥株式會社宣布推出用於治療脊髓性肌肉萎縮症（SMA）的Evrisdi乾糖漿60毫克（通用名：risdiplam）。
此外，預計主要企業擴大採用合作和協作研究等無機策略將在預測期內推動市場成長。例如，2021年3月，全球SMA研究的主要資助機構脊髓性肌肉萎縮症基金會與美國製藥公司PTC Therapeutics, Inc.達成新的合作，專注於開發新治療方法和再生藥物，以進一步推動SMA和其他神經肌肉疾病的科學研究。
本研究的主要特點
- 本報告對全球脊髓性肌肉萎縮症市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模和年複合成長率（CAGR%）。
- 它還強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。
- 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的主要考察。
- 全球脊髓性肌肉萎縮症市場的主要企業是根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數進行的分析。
- 本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
- 全球脊髓性肌肉萎縮症市場報告針對該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進入者和金融分析師1。
- 可以透過用於分析全球脊髓性肌肉萎縮症市場的各種策略矩陣來促進相關人員的決策。
目錄
第1章 調查目的與前提條件
- 研究目標
- 先決條件
- 簡稱
第2章 市場展望
- 報告描述
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章市場動態、法規與趨勢分析
- 市場動態
- 驅動程式
- 限制因素
- 市場機會
- 影響分析
- 市場趨勢
- 收購與合作場景
- 技術進步
- 監管情景
- PEST分析
- 產品發布
4. 全球脊髓性肌肉萎縮症市場-冠狀病毒（COVID-19）大流行的影響
- 整體影響
- 政府舉措
- COVID-19 市場影響
5. 2020 年至 2032 年全球脊髓性肌肉萎縮症市場（按類型）
- I型
- II型
- III型
- 類型IV
6. 2020 年至 2032 年全球脊髓性肌肉萎縮症市場（依療法分類）
- 基因治療
- 緩解疾病的藥物
7. 2020 年至 2032 年全球脊髓性肌肉萎縮症市場（依年齡分類）
- 嬰兒
- 成人
8. 2020 年至 2032 年按給藥途徑分類的全球脊髓性肌肉萎縮症市場
- 口服
- 注射
9. 2020 年至 2032 年全球脊髓性肌肉萎縮症市場（依通路分類）
- 醫院藥房
- 零售藥局
- 網路藥局
第 10 章。 2020 年至 2032 年按地區分類的全球脊髓性肌肉萎縮症市場
- 北美洲
- 拉丁美洲
- 歐洲
- 亞太地區
- 中東
- 非洲
第11章競爭格局
- Biogen
- CYTOKINETICS
- F. Hoffmann-La Roche Ltd
- Genentech, Inc.
- PTC Therapeutics, Inc.
- Novartis AG
- Ionis Pharmaceuticals
- Chugai Pharmaceutical Co., Ltd.
- NMD PHARMA A/S
- Astellas Pharma Inc.
第 12 章分析師建議
- 機會
- 分析師觀點
- Coherent Opportunity Map
第13章 章節
- 參考
- 調查方法
簡介目錄
Product Code: CMI1920
Global Spinal Muscular Atrophy Market is estimated to be valued at USD 2,018.9 Mn in 2025 and is expected to reach USD 4,898.9 Mn by 2032, growing at a compound annual growth rate (CAGR) of 13.5% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 2,018.9 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 13.50% | 2032 Value Projection: | USD 4,898.9 Mn |
Figure. Spinal Muscular Atrophy Market Share (%), By Region 2025
Spinal muscular atrophy (SMA) is a genetic disease that affects the peripheral nervous system, central nervous system, and voluntary muscle movement (skeletal muscle). SMA is muscular since it primarily affects muscles, which do not receive impulses from the nerve cells. Atrophy is the medical term for shrinking, which is what muscles do when they are not stimulated by nerve cells. SMA is a motor neuron disease that includes the loss of nerve cells termed motor neurons in the spinal cord. It mostly affects infants and children but can also develop in adults. An individual with SMA inherits two copies of a faulty (mutated) or missing survival motor neuron 1 (SMN1) gene.
Market Dynamics
The increasing product launches by the key players in the market are expected to drive the market growth over the forecast period. For instance, in August 2021, Chugai Pharmaceutical Co., Ltd., a drug manufacturer operating in Japan, announced that it had launched Evrysdi Dry Syrup 60 mg (generic name: risdiplam) for the treatment of spinal muscular atrophy (SMA).
Moreover, the increasing adoption of inorganic strategies such as partnerships and collaborations by the key players is expected to drive the market growth over the forecast period. For instance, in March 2021, the Spinal Muscular Atrophy Foundation, the leading funder of SMA research worldwide, and PTC Therapeutics, Inc., a U.S. based pharmaceutical company, entered into a new collaboration focused on developing new treatments and regenerative medicine to further advance scientific research in SMA and other neuromuscular disorders.
Key features of the study:
- This report provides in-depth analysis of the global spinal muscular atrophy market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global spinal muscular atrophy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Biogen, CYTOKINETICS, Hoffmann-La Roche Ltd, Genentech, Inc., PTC Therapeutics, Inc., Novartis AG, Ionis Pharmaceuticals, Chugai Pharmaceutical Co., Ltd., NMD PHARMA A/S, and Astellas Pharma Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global spinal muscular atrophy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global spinal muscular atrophy market
Detailed Segmentation:
- Global Spinal Muscular Atrophy Market, By Type:
- Type I
- Type II
- Type III
- Type IV
- Global Spinal Muscular Atrophy Market, By Treatment:
- Gene Therapy
- Disease-modifying drugs
- Global Spinal Muscular Atrophy Market, By Age Group:
- Infant
- Adult
- Global Spinal Muscular Atrophy Market, By Route of Administration:
- Oral
- Injectables
- Global Spinal Muscular Atrophy Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Spinal Muscular Atrophy Market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Company Profiles
- Biogen
- CYTOKINETICS
- Hoffmann-La Roche Ltd
- Genentech, Inc.
- PTC Therapeutics, Inc.
- Novartis AG
- Ionis Pharmaceuticals
- Chugai Pharmaceutical Co., Ltd.
- NMD PHARMA A/S
- Astellas Pharma Inc
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Treatment
- Market Snapshot, By Age
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Acquisitions and Partnerships Scenario
- Technological Advancements
- Regulatory Scenario
- PEST Analysis
- Product Launches
4. Global Spinal Muscular Atrophy Market- Impact of Coronavirus (Covid-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the market
5. Global Spinal Muscular Atrophy Market, By Type, 2020 - 2032, (US$ Million)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Type I
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
- Type II
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
- Type III
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
- Type IV
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
6. Global Spinal Muscular Atrophy Market, By Treatment, 2020 - 2032, (US$ Million)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Gene Therapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
- Disease-modifying drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
7. Global Spinal Muscular Atrophy Market, By Age, 2020 - 2032, (US$ Million)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Infant
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
- Adult
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
8. Global Spinal Muscular Atrophy Market, By Route of Administration, 2020 - 2032, (US$ Million)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
- Injectables
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
9. Global Spinal Muscular Atrophy Market, By Distribution Channel, 2020 - 2032, (US$ Million)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
10. Global Spinal Muscular Atrophy Market, By Region, 2020 - 2032, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Regions, 2021-2032
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Age, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Age, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Age, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
- UK
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Age, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Age, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Age, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (US$ Million)
- North Africa
- Central Africa
- South Africa
11. Competitive Landscape
- Biogen
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- CYTOKINETICS
- F. Hoffmann-La Roche Ltd
- Genentech, Inc.
- PTC Therapeutics, Inc.
- Novartis AG
- Ionis Pharmaceuticals
- Chugai Pharmaceutical Co., Ltd.
- NMD PHARMA A/S
- Astellas Pharma Inc.
12. Analyst Recommendation
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
13. Section
- References
- Research Methodology
- About Us and Sales Contact
